For HCC, studies indicate that combining PD-1/PD-L1 and CTLA-4 inhibitors can significantly enhance T-cell activation and restore anti-tumor immune responses, particularly in patients who exhibit poor responses to monotherapy [77]. This evidence concerns the gene PDCD1 and neoplasm.